Mr. Capone is a dynamic global biotech/pharmaceutical leader with a thirty-year track record of accelerating breakthrough science and transformative drug therapies through development and commercialization across the numerous companies and organizations he has founded or led. His executive roles in organizations ranging from seed-funded start-ups to leading global biopharma companies, reflect a consistent track record of establishing and leading high performing teams to drive innovative drug development through strategic and operational effectiveness to achieve corporate and shareholder value through product portfolio development results. He most recently served as Chief Business Officer of GeneCentric Therapeutics, prior to which he served as CEO and President of the Multiple Myeloma Research Foundation (MMRF) and the Multiple Myeloma Research Consortium (MMRC), advancing industry, academic research, government agency and patient community collaborations to drive breakthroughs for patients. Prior to the MMRF, Walter had over 20 years of pharmaceutical and biotechnology leadership experience in Commercial Development, Operations, Finance, Marketing and Sales in the United States and internationally at Progenics Pharmaceuticals, Trimeris Inc., Triangle Pharmaceuticals, Bristol-Myers Squibb, Wyeth, Cyanamid Benelux and Lederle. He obtained his MBA Columbia University Business School and BA from Brown University.